Oncovita et l’Institut Pasteur annoncent la création d’un laboratoire commun dédié à l’immunothérapie du cancer et la vaccinologie prophylactique Paris le 29 mai 2024 – Dédié à la recherche de nouveaux vaccins immuno-thérapeutiques en oncologie et de vaccins prophylactiques de maladies contagieuses, l’objectif du laboratoire commun
Oncovita and Institut Pasteur announce the creation of a joint laboratory dedicated to cancer immunotherapy and prophylactic vaccinology Voir la version française Paris, 29 May 2024 – Dedicated to the research of new immunotherapeutic vaccines in oncology and prophylactic vaccines for contagious diseases, the aim of the joint Institut Pasteur –
Oncovita, winner of the « Innovations in biotherapies and biomanufacturing » call for projects, will benefit from €4.5 million in funding under the France 2030 investment plan, and has completed a €3.5 million round of financing from private investors to support the development of its MVdeltaC immunotherapeutic vaccine in oncology. Voir la version française
October, 2023 Abstract The measles vaccine (MV) delivery platform has undergone development from preclinical to clinical stages, demonstrating its ability to adapt rapidly and effectively to different pathogens. The live pediatric MV holds extensive history of safety and efficacy, along with its established large-scale manufacturing capacity. To further